These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 16720854)

  • 1. Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of topotecan.
    Muggia F; Kosloff R; Liebes L; Hochster H
    Oncologist; 2006 May; 11(5):529-31; author reply 531-2. PubMed ID: 16720854
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolonged survival with continuous infusion topotecan: a report of 2 cases.
    Klopfenstein KJ; Scott S; Schuller DE; Ruymann FB
    J Pediatr Hematol Oncol; 2008 Jun; 30(6):468-70. PubMed ID: 18525467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb R; Mutch DG
    Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
    Coleman RL; Gordon A; Barter J; Sun S; Rackoff W; Herzog TJ
    Oncologist; 2007 Jan; 12(1):72-8. PubMed ID: 17227902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
    Spannuth WA; Leath CA; Huh WK; Barnes MN; Davidson SA; Kilgore LC; Partridge EE; Austin JM; Alvarez RD
    Gynecol Oncol; 2007 Mar; 104(3):591-5. PubMed ID: 17045635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma.
    Grabenbauer GG; Buchfelder M; Schrell U; Fahlbusch R; Sauer R; Staab HJ
    Front Radiat Ther Oncol; 1999; 33():364-8. PubMed ID: 10549508
    [No Abstract]   [Full Text] [Related]  

  • 7. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
    Stathopoulos GP; Malamos NA; Aravantinos G; Rigatos S; Christodoulou Ch; Stathopoulos J; Skarlos D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):123-8. PubMed ID: 17111119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma.
    Muntz HG; Malpass TW; McGonigle KF; Robertson MD; Weiden PL
    Cancer; 2008 Aug; 113(3):490-6. PubMed ID: 18521923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis.
    Möbus V; Kieback DG; Kaubitzsch SK
    Anticancer Res; 2007; 27(3B):1581-7. PubMed ID: 17595779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
    O'Brien ME; Ciuleanu TE; Tsekov H; Shparyk Y; Cuceviá B; Juhasz G; Thatcher N; Ross GA; Dane GC; Crofts T
    J Clin Oncol; 2006 Dec; 24(34):5441-7. PubMed ID: 17135646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
    Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G
    J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943.
    Seibel NL; Krailo M; Chen Z; Healey J; Breitfeld PP; Drachtman R; Greffe B; Nachman J; Nadel H; Sato JK; Meyers PA; Reaman GH
    Cancer; 2007 Apr; 109(8):1646-53. PubMed ID: 17334983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
    Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
    Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of periocular topotecan in children with intraocular retinoblastoma.
    Chantada GL; Fandino AC; Carcaboso AM; Lagomarsino E; de Davila MT; Guitter MR; Rose AB; Manzitti J; Bramuglia GF; Abramson DH
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1492-6. PubMed ID: 18978345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma.
    Panetta JC; Schaiquevich P; Santana VM; Stewart CF
    Clin Cancer Res; 2008 Jan; 14(1):318-25. PubMed ID: 18172284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
    Shah C; Ready N; Perry M; Kirshner J; Gajra A; Neuman N; Garziano S
    Lung Cancer; 2007 Jul; 57(1):84-8. PubMed ID: 17399850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy.
    Carcaboso AM; Bramuglia GF; Chantada GL; Fandiño AC; Chiappetta DA; de Davila MT; Rubio MC; Abramson DH
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3761-7. PubMed ID: 17652749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
    Safra T; Menczer J; Bernstein R; Shpigel S; Inbar MJ; Grisaru D; Golan A; Levy T
    Gynecol Oncol; 2007 Apr; 105(1):205-10. PubMed ID: 17239430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interspecies scaling of a camptothecin analogue: human predictions for intravenous topotecan using animal data.
    Ahlawat P; Srinivas NR
    Xenobiotica; 2008 Nov; 38(11):1377-85. PubMed ID: 18946781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.
    Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E
    Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.